

**Technology Appraisal**

**Capsule sponge tests for detection of Barrett's oesophagus and early-stage oesophageal cancer and surveillance of Barrett's oesophagus [ID6683]**

**Final Stakeholder List**

<b>Provisional Consultees</b>	<b>Provisional Commentators (no right to submit or appeal)</b>
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Cyted Health (EndoSign)</li> <li>• Medtronic (Cytosponge)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action Against Heartburn</li> <li>• Black Health Agency for Equality</li> <li>• Cancer52</li> <li>• Cancer Black Care</li> <li>• Get A-Head</li> <li>• Guts UK</li> <li>• Head and Neck Cancer UK (HANCUK)</li> <li>• Heartburn Cancer UK</li> <li>• Helen Rollason Cancer Charity</li> <li>• Independent Cancer Patients Voice</li> <li>• Living with Reflux</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie</li> <li>• OCHRE</li> <li>• OG Support UK</li> <li>• OPA Cancer Charity - Oesophageal and Gastric Support</li> <li>• Oracle Head and Neck Cancer UK</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Swallows - Head and Neck Cancer Support Group</li> <li>• Tenovus Cancer Care</li> <li>• United Kingdom and Ireland Oesophagogastric Cancer Group</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Association of British Healthcare Industries (ABHI)</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• Care Quality Commission</li> <li>• Community Pharmacy England</li> <li>• Department of Health - Northern Ireland</li> <li>• HealthTech Alliance</li> <li>• Healthcare Improvement Scotland</li> <li>• Health Technology Wales</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Confederation</li> <li>• NHS Wales Joint Commissioning Committee</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Government</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• Institute of Cancer Research</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul> <p><u>Evidence Review Group</u></p>

Final stakeholder list for the evaluation of Capsule sponge tests for detection of Barrett's oesophagus and early-stage oesophageal cancer and surveillance of Barrett's oesophagus [ID6683]

Issue date: January 2026

© National Institute for Health and Care Excellence 2026. All rights reserved. 1 of 3

<b>Provisional Consultees</b>	<b>Provisional Commentators (no right to submit or appeal)</b>
<ul style="list-style-type: none"> <li>• Association of Palliative Care Medicine of Great Britain</li> <li>• Association of Anaesthetists of Great Britain and Ireland</li> <li>• Association for Clinical Biochemistry and Laboratory Medicine</li> <li>• Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland</li> <li>• BASO - The Association for Cancer Surgery</li> <li>• British Geriatrics Society</li> <li>• British In Vitro Diagnostics Association</li> <li>• British Medical Association</li> <li>• British Oncology Pharmacy Association</li> <li>• British Psychosocial Oncology Society</li> <li>• British Society Gastrointestinal and Abdominal Radiology</li> <li>• British Society of Gastroenterology</li> <li>• Cancer Research UK</li> <li>• Nursing and Midwifery Council</li> <li>• Primary Care Society for Gastroenterology</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Physicians and Surgeons of Glasgow</li> <li>• Royal College of Surgeons of Edinburgh</li> <li>• Royal College of Surgeons of England</li> <li>• Royal Society of Medicine</li> <li>• Welsh Cancer Network</li> <li>• Welsh Association Gastroenterology and Endoscopy</li> <li>• UK Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> <li>• West Yorkshire Integrated Care Board</li> </ul>	<ul style="list-style-type: none"> <li>• School of Health and Related Research (ScHARR)</li> <li>• National Institute for Health Research Health Technology Assessment Programme (NETSCC)</li> </ul> <p><u>Associated Guideline Group</u></p> <ul style="list-style-type: none"> <li>• Scottish Intercollegiate Guidelines Network</li> </ul>

Final stakeholder list for the evaluation of Capsule sponge tests for detection of Barrett's oesophagus and early-stage oesophageal cancer and surveillance of Barrett's oesophagus r [ID6683]

Issue date: January 2026

© National Institute for Health and Care Excellence 2026. All rights reserved. 2 of 3

<b>Provisional Consultees</b>	<b>Provisional Commentators (no right to submit or appeal)</b>
<ul style="list-style-type: none"> <li>NHS Surrey Heartlands Integrated Care Board</li> </ul>	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

**Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

**Consultees**

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

**Commentators**

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.